Emerging IgAN Therapies Bring Hope – But Patients Still Face Emotional and Financial Barriers, According to Spherix Global Insights
Fielded in early 2025 and developed in collaboration with the American Kidney Fund (AKF), the study reflects the voices of 127 patients diagnosed with IgAN. While many report satisfaction with newer branded therapies, substantial gaps persist in patient education, confidence, and affordability. The emotional burden of an IgAN diagnosis remains significant, with most respondents describing initial feelings of fear, confusion, or anxiety.
A clear need emerged for better disease education – particularly around treatment expectations, progression, and financial resources. More than one-third of patients rely on support groups or charitable foundations for financial assistance, underscoring the role pharmaceutical companies can play in reducing barriers through accessible, patient-friendly resources.
The research places special emphasis on patients currently treated with Tarpeyo, Filspari, and Fabhalta, all of which are associated with symptom relief and improved quality of life. However, challenges persist. Although many patients begin treatment feeling informed, issues related to cost, insurance coverage, and long-term affordability often complicate therapy initiation and adherence. These findings highlight opportunities for manufacturers to enhance onboarding and support through both provider-facing tools and direct-to-patient engagement strategies.
The study also integrates insights from Spherix's latest Patient Chart Dynamix™: IgAN (US) study to provide complementary perspectives from nephrologists, offering a comprehensive view of how patient and physician perceptions align, and differ, when it comes to disease severity, treatment satisfaction, and care coordination.
For commercial, medical, and access teams preparing to launch or expand within the IgAN space, Patient Dynamix™: IgAN (US) offers a critical resource for shaping brand strategy, refining support services, and ultimately improving patient outcomes. By leveraging these patient-level insights, pharmaceutical organizations can more effectively tailor messaging, reduce drop-off rates, and enhance their position as true partners in IgAN care.
About Spherix Global Insights
Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle.
The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community.
As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth.
To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn.
About the American Kidney Fund
The American Kidney Fund (AKF) fights kidney disease on all fronts as the nonprofit with the greatest direct impact on people with kidney disease. AKF works on behalf of 1 in 7 Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. AKF fights for kidney health for all through programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy.
AKF is one of the nation's top-rated nonprofits, investing 97 cents of every donated dollar in programs, and it has received 24 consecutive 4-Star ratings from Charity Navigator as well as the Platinum Seal of Transparency from Candid, formerly known as GuideStar.
AKF Contacts
NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
7 hours ago
- Time Business News
Cutting-Edge Innovations in MicroRNA Therapeutics and Diagnostics
MicroRNA is small, non-coding RNA molecules that prevent the production of specific proteins, regulating gene expression by tying the messenger RNA (MRNA). They play an important role in many biological processes, including development, cell discrimination, metabolism and disease progression. MicroRNA growth of the microRNA market is inspired by increasing prevalence of chronic diseases such as cancer and cardiovascular disorders, increasing interest in MIRNA, and progress in sequencing technologies and distribution systems that enable more accurate and efficient applications in diagnosis as diagnostic biomarkers, increasing intensity in MIRNA, and sequencing technologies and distribution systems. Key Growth Drivers and Opportunities Increasing Prevalence of Chronic Diseases: The growing prevalence of chronic diseases such as cancer, cardiovascular disorders, neurological conditions and diabetes is a major driver of the microRNA market, as these diseases often include abnormal gene expression patterns that help to regulate microRNA. MicroRNA works as both medical targets and clinical biometers due to their ability to affect multiple genes and routes simultaneously. As researchers and healthcare providers seek more accurate, initial detection equipment and personal treatment options, increasing demand for MIRNA-based diagnosis and medical science. This has expanded investment in MIRNA research and commercialization, which has increased the market. Challenges Despite its ability, the microRNA market faces several boundaries, including challenges in delivery methods, off-target effects and stability of miRNA molecules in biological environment. Ensuring safe, efficient and tissue-specific distribution is a major obstacle for medical applications. Additionally, the complexity of MIRNA interaction where a miRNA can regulate many genes and vice versa it is difficult to accurately predict the results. Regulatory uncertainty and high growth costs lead to further market growth, obstructing commercialization and clinical adoption. Innovation and Expansion Regulus Therapeutics to Be Acquired by Novartis, Promoting ADPKD MicroRNA Therapy In April 2025, Novartis declared that it has reached a deal to buy Regulus Therapeutics, a publicly listed clinical-stage biopharmaceutical business located in San Diego that specializes in creating microRNA treatments. Farabursen, the main product of Regulus, is a possible first-in-class, next-generation oligonucleotide that targets miR-17 and is used to treat ADPKD. The agreement makes use of our strength and experience in renal illness and is entirely consistent with Novartis' therapeutic area emphasis. Farabursen is an experimental microRNA inhibitor that targets miR-17 with preferential kidney exposure in an effort to slow the evolution of ADPKD disease severity and decrease kidney size and cyst growth. The outcomes from the Phase 1b study demonstrated encouraging clinical effectiveness and safety, with consistent effects on height-adjusted total kidney volume (htTKV), a measure of progressing illness, and urine polycystin (PC), a biomarker of mechanistic response. Inventive Sparks, Expanding Markets The key players operating the MicroRNA market includes, Thermo Fisher Scientific, Illumina, QIAGEN, NEB, Takara Bio, Agilent Technologies, NanoString Technologies Inc., Bio-Rad Laboratories, Roche, GeneCopoeia, and others. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Business Wire
12 hours ago
- Business Wire
Grove Biopharma to Participate in Materials Biology Symposium at ACS Fall 2025 Scientific Meeting
CHICAGO--(BUSINESS WIRE)--Grove Biopharma, a private biotechnology company pioneering its Bionic Biologics™ platform to develop therapies targeting previously intractable intracellular disease targets, announced today it will present an update at the annual American Chemical Society (ACS) Fall meeting being held August 17-21, 2025, in Washington D.C. This symposium spotlights how advances in modern polymer chemistry and materials science are informing our understanding of biology Share The symposium, taking place on Monday, August 18 and titled Materials Biology: Precision Macromolecules for Probing and Perturbing Cellular Processes, will include presentations about peptide, protein and glycomimetic materials and the critical role they play in understanding and impacting human disease. These insights have the potential to unlock new therapeutic strategies in the development of next-generation medicines. 'This symposium spotlights how advances in modern polymer chemistry and materials science are informing our understanding of biology,' said Nathan Gianneschi, Ph.D., Scientific Founder of Grove Biopharma and Professor at Northwestern University. 'By designing synthetic polymers that can precisely interact with cells and proteins at the same scale as natural biomolecules, we are opening new pathways to study and influence complex cellular processes. This emerging field, what we call 'materials biology', is focused on the role of synthetic precision macromolecules and nanomaterials in understanding the natural world.' 'At Grove, we are pioneering Bionic Biologics—a new class of therapeutics that integrates biologic and synthetic design, accelerated by computation, to develop molecules capable of selectively inhibiting or degrading even the most challenging intracellular targets,' said Paul Bertin, Ph.D., Co-Founder, President and Chief Technology Officer at Grove Biopharma. 'By integrating protein and peptide engineering, precision polymer chemistry and medicinal chemistry, we can create fully synthetic, cell penetrant, protein-scale molecules to address complex protein-scale problems. We see the potential for Bionic Biologics in oncology and neurodegenerative diseases, offering a novel alternative to existing approaches.' About Grove Biopharma Grove Biopharma is a private biotechnology company pioneering its proprietary Bionic Biologics™ platform to develop novel therapies targeting intracellular protein-protein interactions. Bionic Biologics represent a novel therapeutic modality that integrates principles of biologic and synthetic design. This innovative platform enables the targeting of well-validated yet previously intractable disease drivers, unlocking new possibilities for therapeutic intervention. A spinout from Northwestern University, Grove brings together a multidisciplinary team of chemists, biologists, materials scientists and entrepreneurs. The company is based in Chicago, embedded within the city's emerging life sciences ecosystem. For more information, please visit
Business Wire
a day ago
- Business Wire
Tivic Reports Second Quarter 2025 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (NASDAQ: TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025. 'We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems,' stated Tivic CEO Jennifer Ernst. 'To maximize our focus on the compelling, late-stage clinical pipeline, we have increasingly shifted resources away from consumer healthtech and are now planning to exit the ClearUP business by the end of this year,' continued Ernst. 'I look forward to advancing the commercialization of these life-saving therapies, supporting our strategy to increase shareholder value through this transformation.' Corporate Highlights from the Second Quarter and Subsequent Weeks, included: Securing positive interest in potential military and defense applications for drug candidate Entolimod™ to treat ARS during briefings with the White House and U.S. Food & Drug Administration (FDA) officials. Extending the worldwide license of Entolimod™ to include the treatment of neutropenia, a condition that reduces the body's ability to combat infections and has a wide range of causes - from genetics to cancer treatments and age. Entering into a GMP manufacturing validation agreement with Scorpius Biomanufacturing, Inc. as part of preparing for the FDA biologics license application process. Completing all study visits in the Optimization Study for its patent-pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Raising $1.4 million from the first and second tranche of a preferred equity purchase agreement that provides for up to $8.4 million in total financing. Entering into a $25 million equity line of credit that generated net proceeds of $547,000. Receiving shareholder approval of key measures in support of Tivic transformation strategy. Expanding biopharmaceutical team with regulatory, clinical and business development staff. Naming Lisa Wolf as CFO following her nine-month tenure as interim CFO. Financial Performance: Revenue (net of returns) for the three and six months ended June 30, 2025 totaled $86,000 and $156,000, respectively, compared with $140,000 and $474,000 for 2024. The decreases are due to lower unit sales of ClearUP™ to treat sinus pain and pressure. The lower sales are attributable to decreases in advertising expenses as the company focused resources on accelerating its TLR5 program for the development of Entolimod™ for ARS. Gross profit in the three and six months ended June 30, 2025 was $54,000 and $104,000, respectively, compared to $30,000 and $197,000 in 2024. Gross margin was 67% in the six months ended June 30, 2025, compared to 42% in 2024. Operating expenses in the three and six months ended June 30, 2025 was $2.0 million and $3.5 million, respectively, compared to $1.3 million and $3.0 million in 2024. The increases were primarily due to the addition of the biopharma programs in February 2025. Net loss of $1.9 million for the three months ended June 30, 2025, compared to $1.3 million in the second quarter of 2024. Net loss of $3.4 million for the first half of 2025, compared to $2.7 million for the first half of 2024. At June 30, 2025, cash and cash equivalents totaled $1.2 million, compared with $2.0 million, at December 31, 2024. Subsequent to quarter's end, the Company raised a total of $0.9 million through utilization of its equity line of credit and the sale of Series B Preferred Stock pursuant to its preferred equity purchase agreement. The company has no debt on its balance sheet. Approximately $7.0 million remains available as a committed investment in Tivic through a preferred equity purchase agreement. The company believes the current and committed funding is sufficient to make meaningful progress toward manufacturing validation for Entolimod. Conference Call and Webcast Information Management will host a webcast/conference call today, Thursday, August 14, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the company's second quarter 2025 financial results and provide a business update. Webcast Link An audio replay of the call will be available for the next 90 days from the investor page on the Tivic Health website at About Tivic Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors," as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law. Tivic Health Systems, Inc. Condensed Statements of Operations (in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 REVENUES $ 86 $ 140 $ 156 $ 474 COST OF SALES 32 110 52 277 GROSS PROFIT 54 30 104 197 OPERATING EXPENSES Research and development 655 302 990 558 Sales and marketing 426 207 605 712 General and administrative 907 787 1,949 1,674 TOTAL OPERATING EXPENSES 1,988 1,296 3,544 2,944 NET OPERATING LOSS (1,934 ) (1,266 ) (3,440 ) (2,747 ) OTHER INCOME, NET 3 0 7 0 NET LOSS $ (1,931 ) $ (1,266 ) $ (3,433 ) $ (2,747 ) NET LOSS PER SHARE - BASIC AND DILUTED $ (2.19 ) $ (5.37 ) $ (4.64 ) $ (17.05 ) WEIGHTED-AVERAGE NUMBER OF SHARES - BASIC AND DILUTED 881,294 235,868 739,618 161,103 Expand
